HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Extended-release metformin does not reduce the clomiphene citrate dose required to induce ovulation in polycystic ovary syndrome.

AbstractCONTEXT:
When used for ovulation induction, higher doses of clomiphene may lead to antiestrogenic side effects that reduce fecundity. It has been suggested that metformin in combination with clomiphene can restore ovulation to some clomiphene-resistant anovulators with polycystic ovary syndrome (PCOS).
OBJECTIVE:
Our objective was to determine if cotreatment with extended-release metformin (metformin XR) can lower the threshold dose of clomiphene needed to induce ovulation in women with PCOS.
DESIGN:
A secondary analysis of data from the National Institute of Child Health and Human Development Cooperative Multicenter Reproductive Medicine Network prospective, double-blind, placebo-controlled multicenter clinical trial, Pregnancy in Polycystic Ovary Syndrome, was performed.
SETTING:
Study volunteers at multiple academic medical centers were included.
PARTICIPANTS:
Women with PCOS and elevated serum testosterone who were randomized to clomiphene alone or with metformin (n = 209 in each group) were included in the study.
INTERVENTIONS:
Clomiphene citrate, 50 mg daily for 5 d, was increased to 100 and 150 mg in subsequent cycles if ovulation was not achieved; half also received metformin XR, 1000 mg twice daily. Treatment was for up to 30 wk or six cycles, or until first pregnancy.
MAIN OUTCOME MEASURES:
Ovulation was confirmed by a serum progesterone more than or equal to 5 ng/ml, drawn prospectively every 1-2 wk.
RESULTS:
The overall prevalence of at least one ovulation after clomiphene was 75 and 83% (P = 0.04) for the clomiphene-only and clomiphene plus metformin groups, respectively. Using available data from 314 ovulators, the frequency distribution of the lowest clomiphene dose (50, 100, or 150 mg daily) resulting in ovulation was indistinguishable between the two treatment groups.
CONCLUSION:
Metformin XR does not reduce the lowest dose of clomiphene that induces ovulation in women with PCOS.
AuthorsNicholas A Cataldo, Huiman X Barnhart, Richard S Legro, Evan R Myers, William D Schlaff, Bruce R Carr, Michael P Diamond, Sandra A Carson, Michael P Steinkampf, Christos Coutifaris, Peter G McGovern, Gabriella Gosman, John E Nestler, Linda C Giudice,
JournalThe Journal of clinical endocrinology and metabolism (J Clin Endocrinol Metab) Vol. 93 Issue 8 Pg. 3124-7 (Aug 2008) ISSN: 0021-972X [Print] United States
PMID18505764 (Publication Type: Journal Article, Multicenter Study, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • Delayed-Action Preparations
  • Fertility Agents, Female
  • Clomiphene
  • Metformin
Topics
  • Adult
  • Clomiphene (administration & dosage)
  • Delayed-Action Preparations
  • Female
  • Fertility Agents, Female (administration & dosage)
  • Humans
  • Metformin (administration & dosage)
  • Ovulation Induction
  • Polycystic Ovary Syndrome (drug therapy, physiopathology)
  • Prospective Studies
  • Randomized Controlled Trials as Topic

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: